Ticker > Company >

Genomic Valley share price

Genomic Valley Biotech Ltd.

BSE: 539206 SECTOR: Agriculture  12k   27   2

46.08
-2.42 (-4.99%)
BSE: 31 Jan 04:01 PM

Price Summary

Today's High

₹ 47

Today's Low

₹ 46.08

52 Week High

₹ 108.15

52 Week Low

₹ 28.36

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

14.08 Cr.

Enterprise Value

14.07 Cr.

No. of Shares

0.31 Cr.

P/E

55.41

P/B

3.69

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  12.5

CASH

0.01 Cr.

DEBT

0 Cr.

Promoter Holding

46.83 %

EPS (TTM)

₹  0.83

Sales Growth

-93.94%

ROE

0.43 %

ROCE

0.45%

Profit Growth

-97.66 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-93.94%
3 Year-7.43%
5 Year-30.04%

Profit Growth

1 Year-97.66%
3 Year26.56%
5 Year-42.06%

ROE%

1 Year0.43%
3 Year6.81%
5 Year2.9%

ROCE %

1 Year0.45%
3 Year7.24%
5 Year4.54%

Debt/Equity

0

Price to Cash Flow

-701.3

Interest Cover Ratio

24.4018

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 46.83 0.00
Sep 2024 54.67 0.00
Jun 2024 64.14 0.00
Mar 2024 64.20 0.00
Dec 2023 65.04 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 3.6768.

 Limitations

  • The company has shown a poor revenue growth of -7.4271481829651% for the Past 3 years.
  • Company has a poor ROE of 6.80547240969932% over the past 3 years.
  • Company has high debtor days of 5248.7442.
  • Company has negative cash flow from operations of -0.0200702.
  • The company has a low EBITDA margin of -98.6583132822834% over the past 5 years.
  • The company is trading at a high PE of 55.41.
  • The company is trading at a high EV/EBITDA of 53.5535.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 0.07 0.04 0 0.16 0.21
Total Expenditure 0.04 0.02 0.04 0.03 0.06
Operating Profit 0.02 0.02 -0.04 0.13 0.14
Other Income 0 0 0 0 0.01
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.02 0.02 -0.04 0.13 0.15
Tax 0 0 0 0 0
Profit After Tax 0.02 0.02 -0.04 0.13 0.15
Adjusted EPS (Rs) 0.08 0.08 -0.14 0.42 0.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0.85 0.21 0.07 2.72 0.17
Total Expenditure 0.29 0.34 0.45 1.84 0.15
Operating Profit 0.55 -0.14 -0.38 0.88 0.02
Other Income 0.01 0 0.08 0.04 0
Interest 0.18 0.18 0.04 0 0
Depreciation 0.18 0.19 0.08 0.01 0
Exceptional Items 0 0 0.42 -0.26 0
Profit Before Tax 0.21 -0.5 0 0.65 0.02
Tax -0.08 0.06 0.01 0 0
Net Profit 0.29 -0.56 -0.01 0.65 0.02
Adjusted EPS (Rs.) 0.94 -1.83 -0.03 2.12 0.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 3.05 3.05 3.05 3.05 3.05
Total Reserves 1.99 1.43 -0.18 0.47 0.49
Borrowings 1.48 1.55 0 0 0
Other N/C liabilities 0.65 0.7 0.7 0 0
Current liabilities 0.77 0.87 0.21 0.89 0.79
Total Liabilities 7.94 7.61 3.8 4.42 4.33
Assets
Net Block 4.47 5.86 1.75 0 0
Capital WIP 0.49 0.49 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0.02
Loans & Advances 2.58 1.1 0.91 1.84 1.41
Other N/C Assets 0 0 0 0 0
Current Assets 0.4 0.16 1.14 2.58 2.91
Total Assets 7.94 7.61 3.8 4.42 4.33
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.21 -0.5 -0.42 0.91 0.02
Adjustment 0.18 0.19 -0.26 -0.03 0
Changes in Assets & Liabilities 0.06 1.8 -1.45 -1.66 -0.03
Tax Paid 0 0 0 0 0
Operating Cash Flow 0.44 1.48 -2.13 -0.78 -0.02
Investing Cash Flow -0.47 -1.58 3.67 1.52 -0.02
Financing Cash Flow 0 0.07 -1.55 -0.7 0
Net Cash Flow -0.04 -0.03 -0.01 0.04 -0.04

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 65.04 64.20 64.14 54.67 46.83
ojaswini avantika 0.07 0.07 0.07 0.07 0.07
yogesh agrawal 55.69 54.85 54.78 50.70 46.76
parul agrawal 9.29 9.29 9.29 3.91 -
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 34.96 35.80 35.86 45.33 53.17
amar aggarwal 9.05 9.05 9.05 9.05 9.05
deepti aggarwal 11.00 11.00 11.00 11.00 11.00
purushothaman shaji - - - - 2.53
vikram ashokkumar jain - - - - 5.50
harish chandra sharma 4.81 4.81 4.81 2.87 -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Genomic Valley Biotech informs about disclosure 18 Oct, 12:20 PM Genomic Valley - Quaterly Results 7 Oct, 4:07 PM Genomic Valley - Quaterly Results 7 Oct, 4:07 PM Genomic Valley - Quaterly Results 7 Oct, 4:07 PM Genomic Valley Biotech submits board meeting intimation 3 Oct, 4:38 PM Genomic Valley Biotech informs about disclosure 19 Sep, 11:08 AM Genomic Valley Biotech informs about disclosure 26 Aug, 3:33 PM Genomic Valley Biotech informs about newspaper advertisement 1 Aug, 9:45 AM Genomic Valley - Quaterly Results 29 Jul, 5:55 PM Genomic Valley - Quaterly Results 29 Jul, 5:55 PM Genomic Valley - Quaterly Results 29 Jul, 5:55 PM Genomic Valley - Quaterly Results 9 May, 7:11 PM Genomic Valley - Quaterly Results 9 May, 7:11 PM Genomic Valley Biotech submits compliance certificate 30 Apr, 9:52 AM Genomic Valley - Quaterly Results 14 Feb, 6:48 PM Genomic Valley Biotech informs about certificate 11 Jan, 5:20 PM Genomic Valley - Quaterly Results 10 Feb, 1:58 PM Genomic Valley - Quaterly Results 10 Feb, 1:58 PM Genomic Valley - Quaterly Results 10 Feb, 1:58 PM Genomic Valley Biotech informs about appointment of company secretary 21 Dec, 3:21 PM Genomic Valley Biotech informs about newspaper publication 8 Dec, 2:57 PM Genomic Valley Biotech informs about annual report 7 Dec, 3:55 PM Genomic Valley Biotech informs about disclosure of related party transactions 26 Nov, 3:19 PM Genomic Valley - Quaterly Results 20 Jul, 1:16 PM Genomic Valley - Quaterly Results 20 Jul, 1:16 PM Genomic Valley - Quaterly Results 20 Jul, 1:16 PM Genomic Valley Biotech informs about disclosure 13 May, 4:53 PM Genomic Valley - Quaterly Results 12 Feb, 3:18 PM Genomic Valley Biotech informs about newspaper advertisements 4 Feb, 4:16 PM Genomic Valley Biotech informs about certificate 11 Jan, 2:53 PM Genomic Valley Biotech informs about newspaper advertisements 9 Dec, 4:57 PM Genomic Valley Biotech informs about AGM 8 Dec, 12:37 PM Genomic Valley Biotech informs about book closure 7 Dec, 4:06 PM Genomic Valley Biotech informs about appointment of CS cum CO 6 Dec, 2:02 PM Genomic Valley Biotech informs about outcome of board meeting 25 Nov, 9:49 AM Genomic Valley Biotech informs about trading window closure 1 Nov, 4:27 PM Genomic Valley Biotech informs about board meeting 1 Nov, 4:19 PM Genomic Valley Biotech informs about certificate 14 Oct, 3:47 PM Genomic Valley Biotech informs about board meeting 2 Aug, 3:08 PM Genomic Valley Biotech informs about resignation of CS cum CO 10 Jun, 12:25 PM Genomic Valley Biotech informs about certificate 16 Apr, 12:18 PM Genomic Valley Biotech informs about disclosure 30 Nov, 4:44 PM

Genomic Valley Stock Price Analysis and Quick Research Report. Is Genomic Valley an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Genomic Valley stock price today is Rs 46.08. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Genomic Valley . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Genomic Valley has a PE ratio of 55.4112554112554 which is high and comparatively overvalued .

  • Share Price: - The current share price of Genomic Valley is Rs 46.08. One can use valuation calculators of ticker to know if Genomic Valley share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Genomic Valley has ROA of 0.3469 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Genomic Valley has a Current ratio of 3.6768 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Genomic Valley has a ROE of 0.4295 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Genomic Valley has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Genomic Valley has reported revenue growth of -93.9367 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Genomic Valley for the current financial year is 9.32152052097531 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Genomic Valley is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Genomic Valley is Rs 0.8316 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Genomic Valley in Ticker for free. Also, one can get the intrinsic value of Genomic Valley by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Genomic Valley
X